GPR133 Antibody

What is GPR133 and why is it significant in research?

GPR133 (also known as ADGRD1) is an adhesion G protein-coupled receptor involved in raising cytosolic cAMP levels. It has gained significant research interest because it is necessary for the growth of glioblastoma (GBM) and is expressed de novo in GBM relative to normal brain tissue . This differential expression pattern makes GPR133 a potential therapeutic target for GBM treatment, which has driven the development of antibodies against this receptor for both research and potential therapeutic applications.

What types of GPR133 antibodies are available for research?

GPR133 antibodies available for research include both monoclonal and polyclonal antibodies targeting different epitopes of the receptor. These include commercial antibodies targeting the N-terminus, such as those recognizing the PTX domain, as well as antibodies that target the C-terminal fragment (CTF) . Some well-characterized antibodies include the mouse monoclonal antibody 8E3E8 against the PTX domain and various tagged antibodies (anti-HA, anti-FLAG) used in conjunction with tagged GPR133 constructs for research purposes .

What applications are GPR133 antibodies validated for?

Based on available data, GPR133 antibodies have been validated for multiple applications including:

How should GPR133 antibodies be used for Western blot analysis?

For Western blot analysis of GPR133, researchers should consider the following methodological approach:

• Sample preparation: Prepare whole cell lysates from GPR133-expressing cells (either endogenous or overexpressed systems).

• Expected band patterns: When using antibodies against different epitopes, expect to detect:

  • Anti-N-terminus (e.g., anti-HA or 8E3E8): Bands representing maturely and immaturely glycosylated NTF (~95/75 kDa) and some full-length uncleaved receptor (~110 kDa)

  • Anti-C-terminus (e.g., anti-FLAG or anti-CTF): CTF (~25 kDa) and some full-length uncleaved receptor

  • Both antibodies may detect high molecular weight aggregates (>260 kDa)

• Interpretation: The apparent molecular weight of the NTF is affected by glycosylation, while the CTF may show a size shift due to increased SDS loading to hydrophobic transmembrane regions .

What controls should be included when using GPR133 antibodies for signaling studies?

When studying GPR133 signaling with antibodies, essential controls include:

• Negative controls:

  • Cells not expressing GPR133

  • Isotype control antibodies

  • Cleavage-deficient GPR133 mutant (H543R) which does not respond to antibody stimulation

• Positive controls:

  • Known activators of cAMP signaling

  • GPR133 deletion mutants lacking the NTF, which exhibit increased basal signaling

• Specificity controls:

  • Epitope deletion constructs to confirm antibody specificity

  • Concentration-dependent response curves to establish dose-response relationships

How can cross-reactivity of GPR133 antibodies between species be determined?

Determining cross-reactivity of GPR133 antibodies between species requires systematic validation:

• Sequence alignment analysis: Compare the epitope sequence between species to predict potential cross-reactivity.

• Experimental validation: Test antibodies on tissues or cells from different species expressing GPR133. Current data indicates that some commercial anti-GPR133 antibodies react with human and monkey samples, but cross-reactivity with other species (e.g., pig) has not been thoroughly validated .

• Positive and negative controls: Include samples known to express or lack GPR133 from the species of interest.

• Consider innovator programs offered by antibody suppliers that provide incentives for validating antibodies in new species applications .

How do antibodies against the N-terminus activate GPR133 signaling?

The mechanism by which antibodies activate GPR133 signaling involves several steps:

• Binding to the N-terminus: Antibodies bind to epitopes on the N-terminal fragment (NTF) of GPR133, specifically regions outside the GAIN domain .

• Cleavage-dependent activation: The activation is dependent on autoproteolytic cleavage of the receptor, as cleavage-deficient mutants (H543R) do not respond to antibody stimulation .

• Dissociation of fragments: Antibody binding promotes dissociation of the NTF from the C-terminal fragment (CTF) at the plasma membrane .

• Tethered agonist exposure: This dissociation likely unveils an endogenous tethered agonist immediately distal to the GPS autoproteolysis site .

• G protein activation: The exposed tethered agonist activates Gαs signaling, leading to increased cAMP levels in a concentration-dependent manner .

What is the relationship between GPR133 autoproteolytic cleavage and antibody-mediated activation?

The relationship between GPR133 autoproteolytic cleavage and antibody-mediated activation is central to understanding receptor function:

• Prerequisite for activation: Autoproteolytic cleavage of GPR133 at the GPS site (generating separate NTF and CTF) is required for antibody-mediated activation .

• Evidence for cleavage dependency:

  • Cleavage-deficient mutant (H543R) does not respond to antibody treatment that activates wild-type GPR133

  • Following antibody treatment, antibody-NTF complexes are detected in culture medium, suggesting dissociation of these fragments from the cell surface

• Proposed mechanism: Antibodies may facilitate the dissociation of the NTF from the CTF, which correlates with increased receptor signaling. This is supported by observations that GPR133 deletion mutants lacking the NTF exhibit significantly increased signaling relative to the wild-type receptor .

How can bead-coupled antibodies enhance GPR133 activation compared to soluble antibodies?

Bead-coupled antibodies show enhanced ability to activate GPR133 compared to soluble antibodies through several potential mechanisms:

• Increased effective concentration: Antibody-coated beads precipitate onto cell surfaces, significantly increasing the local concentration of antibodies at the plasma membrane .

• Antibody clustering: Bead coupling may promote clustering of antibodies, enhancing their effect on receptor activation .

• Mechanical force application:

  • Beads may provide a rigid surface for antibody attachment, restricting antibody mobility and potentially facilitating NTF-CTF dissociation

  • The physical bulk of beads may apply mechanical forces that help "pull" the NTF off the CTF

  • These mechanical forces may induce conformational changes leading to receptor activation

• Experimental evidence: Microscopy confirms that antibody-coated beads bind specifically to cells expressing tagged GPR133, with reduced mobility compared to unconjugated beads, indicating their interaction with the receptor at the cell surface .

How can GPR133 antibodies be used to study glioblastoma (GBM)?

GPR133 antibodies serve as valuable tools for studying glioblastoma through multiple approaches:

• Expression analysis: Antibodies can be used to detect and quantify de novo expression of GPR133 in GBM tissues compared to normal brain tissue using immunohistochemistry, Western blot, or flow cytometry .

• Functional studies in patient-derived cells:

  • Antibody-mediated stimulation of wild-type GPR133 has been successfully demonstrated in patient-derived GBM cells

  • Comparison with cleavage-deficient H543R mutant can reveal signaling mechanisms specific to GBM

• Therapeutic development:

  • GPR133 antibodies provide a paradigm for modulation of receptor function with biologics

  • They can serve as prototype therapeutic agents targeting GPR133 in GBM, where this receptor plays important roles in tumor growth

• Mechanistic studies: Using antibodies to manipulate GPR133 signaling can help elucidate downstream pathways critical for GBM cell proliferation, migration, and survival .

What are the considerations for designing GPR133 constructs for antibody validation studies?

When designing GPR133 constructs for antibody validation studies, researchers should consider:

• Epitope tagging strategies:

  • N-terminal tags (e.g., HA, Twin-Strep) for tracking the NTF

  • C-terminal tags (e.g., FLAG) for tracking the CTF

  • Dual tagging (e.g., HF-GPR133 with N-terminal HA and C-terminal FLAG) for simultaneous tracking of both fragments

• Cleavage-deficient mutants:

  • H543R point mutation prevents autoproteolytic cleavage and serves as a critical negative control for antibody activation studies

  • Generated through site-directed mutagenesis using kits such as Q5 Site-Directed Mutagenesis Kit

• Domain deletion constructs:

  • PTX domain deletion (ΔPTX) to assess the role of specific domains in antibody binding and activation

  • Generated using Gibson assembly methods

• Expression systems:

  • HEK293T cells are commonly used for initial validation

  • Patient-derived GBM cells provide disease-relevant context

How can antibody-mediated GPR133 activation be quantified and analyzed?

Quantification and analysis of antibody-mediated GPR133 activation can be approached through several complementary methods:

• cAMP level measurement:

  • Direct quantification of cAMP using commercially available assays (e.g., ELISA-based)

  • Concentration-dependent response curves to determine EC50 values for different antibodies

  • Comparison between wild-type and cleavage-deficient mutants

• Biochemical analysis of fragment dissociation:

  • Western blot analysis of culture medium to detect antibody-NTF complexes

  • Quantification of NTF release from cells following antibody treatment

  • Immunoprecipitation to verify specific interactions

• Microscopy-based approaches:

  • Visualization of antibody-coated bead binding to cells expressing tagged GPR133

  • Tracking bead diffusivity over time to assess binding specificity

  • Comparison between cells expressing wild-type versus mutant receptors

• Signaling pathway analysis:

  • Assessment of downstream effects on Gαs signaling

  • Comparison with other known aGPCR activation mechanisms

  • Evaluation of potential therapeutic outcomes in disease models

Why might GPR133 antibodies show variable effectiveness across experiments?

Variability in GPR133 antibody effectiveness can stem from several factors:

• Receptor expression levels: Variation in GPR133 expression between experiments can affect antibody binding and activation potential.

• Post-translational modifications:

  • Glycosylation affects the apparent molecular weight of the NTF (~95/75 kDa for maturely/immaturely glycosylated forms)

  • Changes in glycosylation patterns may influence antibody binding efficiency

• Fragment dissociation dynamics: The research indicates that NTF enrichment in culture medium after antibody treatment was inconsistent, being observed in only half of the experiments, suggesting complex dynamics of NTF-CTF dissociation .

• Experimental conditions: Cell density, culture conditions, and detection methods can all influence experimental outcomes.

• Antibody quality and stability: Repeated freeze-thaw cycles can reduce antibody effectiveness; storage recommendations typically suggest -20°C for long-term storage and 4°C for up to one month for frequent use .

How do GPR133 antibodies compare to other activation mechanisms for adhesion GPCRs?

GPR133 antibodies represent one of several mechanisms for modulating adhesion GPCR activity:

• Comparison with other aGPCR antibody approaches:

  • Similar to CD97 (ADGRE5), where antibodies targeting the N-terminus outside the GAIN domain result in NTF shedding

  • Consistent with EMR2 (ADGRE2) studies showing increased signaling after treatment with N-terminus binding antibodies

• Alternative activation mechanisms:

  • Synthetic peptide agonists mimicking the tethered agonist sequence

  • Mechanical activation through force-induced NTF-CTF dissociation

  • Deletion mutants lacking the NTF that exhibit constitutive activity

• Relative advantages of antibody-based approaches:

  • Specificity for target receptor

  • Potential for modulating rather than completely activating signaling

  • Compatibility with therapeutic development pipelines

  • Ability to be coupled with other molecules or particles (e.g., beads) for enhanced effects

What are the future directions for GPR133 antibody research and development?

Future directions for GPR133 antibody research and development include:

• Therapeutic development for GBM:

  • Optimization of antibodies for maximal activation or inhibition of GPR133

  • Development of humanized antibodies suitable for clinical applications

  • Combination approaches with standard GBM treatments

• Mechanistic investigations:

  • Further elucidation of the precise mechanism by which antibodies promote NTF-CTF dissociation

  • Understanding the role of mechanical forces in antibody-mediated activation

  • Identifying the exact epitopes that yield optimal receptor modulation

• Cross-species applications:

  • Validation of antibodies for use in model organisms to facilitate preclinical studies

  • Development of cross-reactive antibodies to support translational research

• Novel antibody formats:

  • Bispecific antibodies targeting GPR133 and other GBM markers

  • Antibody-drug conjugates for targeted delivery to GPR133-expressing cells

  • Nanobodies or other alternative binding proteins with improved tissue penetration

• Expanded application areas:

  • Investigation of GPR133 in other malignancies beyond GBM

  • Exploration of normal physiological roles of GPR133 using antibody tools